More positive PhIII data set stage for Scynexis' vaginal yeast infection drug approval
Months after unveiling data that showed its lead experimental compound, ibrexafungerp, helped patients with vaginal yeast infections, antifungal drug developer Scynexis is one step closer to the finish line with a second positive pivotal trial.
The company — which burst into the zeitgeist as one of the few companies testing a Candida auris therapy (the same drug ibrexafungerp) in human trials — is gearing up to submit a marketing application in the second half of this year, for what it claims is the first and only oral, non-azole treatment for vaginal yeast infections, a condition that affects three out of four women across their lifetimes but has limited treatment options.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.